Purdue Pharma Completes Ph I for Oncology Therapy Candidate

Purdue Pharma Completes Ph I for Oncology Therapy Candidate

Source: 
CP Wire
snippet: 

Purdue Pharma announced on 6/27/2018 successful completion of a first-in-human Phase 1 dose escalation study of tinostamustine in patients with relapsed or refractory hematological malignancies for which there are no available therapies.